131619Tablet VaccinesClosedFeasibility StudiesInnovate UKAcellular vaccines have an excellent record of safety and efficacy in target paediatric patients but the restricted scope of the immune response and the reduced duration of immunity compared to previous live or attenuated vaccines has led to declining protection for older patients and incomplete herd immunity. For pertussis this has resulted in a recent upsurge of cases across well vaccinated countries. The objective of this project will be to develop innovative tablet vaccine formulations to allow booster acellular vaccines to be taken orally. The formulations will aim to boost systemic antibody titres and induce a mucosal immune response resulting in improved efficacy. Self-administered oral booster vaccines will also lower healthcare costs and encourage better patient compliance, resulting in more extensive community protection within developed and developing world countries